Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria

scientific article published on 13 August 2015

Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/IJC.29805
P698PubMed publication ID26270488

P50authorPeter GibbsQ51552633
Jayesh DesaiQ56580375
Matthew W CroxfordQ63982944
Hui-li WongQ85795055
Natalie TurnerQ85899528
Susie BaeQ87871911
Jeanne TieQ89907190
Arnoud J TempletonQ91787962
Mathuranthakan SinnathambyQ114401193
P2093author name stringIan Jones
Michael Christie
Ben Tran
Sagarika Tripathy
Te Whiti Rogers
P2860cites workTumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancerQ24614511
Inflammation and cancerQ24649640
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysisQ27022482
Towards the introduction of the 'Immunoscore' in the classification of malignant tumoursQ27026489
Immunity, Inflammation, and CancerQ27861048
A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosisQ28269226
Current status of gene expression profiling to assist decision making in stage II colon cancerQ33829763
Effector memory T cells, early metastasis, and survival in colorectal cancerQ33992461
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal CancerQ34062558
Chemoprevention of colorectal cancer: systematic review and economic evaluationQ34123639
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysisQ34188723
Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancerQ34321215
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trialQ34607843
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.Q34806672
Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability statusQ35565700
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancerQ35806164
Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian seriesQ36776983
Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer.Q37003283
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.Q37411227
Cancer-related inflammation and treatment effectivenessQ38256601
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.Q38421451
Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy.Q43686080
Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladderQ44084230
A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancerQ44980730
Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapyQ46721130
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.Q51023201
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.Q51502354
Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma.Q51860276
Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer.Q53362352
Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal CancerQ56601042
P433issue3
P407language of work or nameEnglishQ1860
P921main subjectsystemic inflammationQ7663815
colon cancerQ18555025
P304page(s)671-678
P577publication date2015-08-13
P1433published inInternational Journal of CancerQ332492
P1476titleAnalysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria
P478volume138

Reverse relations

cites work (P2860)
Q33685545Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer
Q92577787Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy
Q36821123Comparison of the prognostic value of measures of the tumor inflammatory cell infiltrate and tumor-associated stroma in patients with primary operable colorectal cancer
Q94603190Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma
Q38995724Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer
Q59354597Human leukocyte antigen gene polymorphisms are associated with systemic inflammation in hepatitis B virus-related hepatocellular carcinoma
Q92510487Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response
Q33762053Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis
Q59794859Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients
Q64106610Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs
Q52884982Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer.
Q64084593Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer
Q57700802Prognostic impact of preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer with special reference to myeloid-derived suppressor cells
Q59136283Prognostic value of inflammation-based scores in patients receiving radical resection for colorectal cancer
Q91658773Relationship between local and systemic inflammatory response and prognosis in laryngeal squamous cell carcinoma
Q92424731Single- versus two-port video-assisted thoracic surgery in mediastinal tumor: a propensity-matched study
Q99726006Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate
Q93184520Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance
Q37222061The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy
Q37441444The prognostic value of systemic and local inflammation in patients with laryngeal squamous cell carcinoma
Q47338550The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.
Q36338120Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer.